NEW YORK--(BUSINESS WIRE)--Lantern Pharma is excited to announce that it has been selected as a "2018 TiE50 Finalist" for the prestigious TiE50 Awards Program recognizing the world's most innovative tech startups. This awards competition is part of TiE Inflect 2018, the world's largest conference for tech entrepreneurs.
“We are honored to have been selected as a 2018 TiE50 Finalist for the esteemed TiE50 Awards Program from more than 7000 companies all around the world. Founded in 2013, Lantern Pharma is rethinking the cancer drug development process, tailoring multiple promising precision drug programs to the right subgroup of cancer patients through use of their RADRTM platform (Response Algorithm for Drug Rescue and Positioning). Right patient stratification is still considered by many in pharma as the holy grail. Lantern is disrupting this using seamless integration of relevant existing data, generation of new clean data closely modeling real world evidence and very focused artificial intelligence technology application to further model this data and distill into meaningful information that can identify & stratify right patients with high accuracy.
"Lantern is currently progressing 3 clinical stage drugs in using this technology. Lantern also have a growing number of partnerships with non-profits, and Academia. We look forward to sharing ideas with the other Finalists, applicants and participants at TiE Inflect 2018.” - Arun Asaithambi, Co-Founder
"TiE50 has become a global brand that attracts thousands of tech startups worldwide. This year, we screened more than 7400 companies from 28 countries and selected the best-of-breed as our "2018 TiE50 Finalists". These companies are finalists in the ultimate runoff for the 50 winners. Our program has gained notoriety over the past decade as a competition run with the highest level of integrity and vigorous screening and judging by domain experts." - Kamal Anand, TiE50 Program Chair
"As a 26-year not-for-profit dedicated to fostering entrepreneurship and with a global footprint of half million entrepreneurs, enterprise executives, and investment professionals, we pride in the fact that we are one of very few competitions without any pay-to-play incentives." - Ram K. Reddy, President, TiE Silicon Valley
About Lantern Pharma Inc
Lantern Pharma is a late clinical stage precision oncology company that is using proprietary tech platform called RADR to identify drug specific complex genetic signatures (potential CDX) for potential responders identification and stratification with a high prediction accuracy to conduct focused precision clinical trials. RADR is integrating any existing clinical data, with data generated from wet-lab approach closely modeling real world evidence/clinical trials and artificial intelligence to identify genetic signatures and right responders. Lantern's approach can improve success of the drug, lower developmental costs and time many folds vs traditional drug developmental processes.
About TiE Inflect 2018:
TiE Inflect (previously TiEcon) is the world's largest conference for entrepreneurs and intrapreneurs with participation from top technology companies, leading venture capital firms, and global services providers. TiEcon 2017 attracted 5400+ attendees from across the world - including CEOs of established companies to first-time entrepreneurs creating new companies, to leading investment professionals and corporate executives. The conference was listed by Worth Magazine as one of the 10 best conferences for ideas and entrepreneurship along with TED and the World Economic Forum. For more information, please visit http://www.tieinflect.org.
The Indus Entrepreneurs (TiE) is a not-for-profit founded in 1992 in the Silicon Valley by a group of successful entrepreneurs, corporate executives, and senior professionals. TiE is the world's largest network of tech entrepreneurs. We are a cohesive global network with a footprint of half million entrepreneurs, enterprise executives, investment professionals, and other accomplished individuals. We operate from 60 cities in 18 countries. http://www.tieeco.org.